Compound
D1013 | nelfinavir mesylate
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 11.88±6.92 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 30.83 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 8.68±12.24 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
|
Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P273, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | ||
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD | oral | > 5gm/kg (5000mg/kg) | Toxicologist. Vol. 42, Pg. 55, 1998. | |
| (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroiso-quinoline-3-carboxylic acid t-butylamide methanesulfonate | (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate | (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate |
| (3S,4aS,8aS)-3-(tert-butylcarbamoyl)-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinolinium methanesulfonate | (3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2- hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate | (3S,4aS,8aS)-N-tert-Butyl-2-((2R,3R)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl)decahydro-3-isoquinolinecarboxamide monomethanesulfonate (salt) |
| (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate | (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (salt) | 159989-65-8 |
| 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-, monomethanesulfonate (salt) | 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2,S*,3S*),3-alpha,4a-beta,8a-beta))-, monomethanesulfonate (salt) | 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, methanesulfonate (1:1) |
| 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, methanesulfonate (3S,4aS,8aS)-; | 3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate | 989N658 |
| 98D603VP8V | AC-20033 | AG 1341 |
| AG 1343 | AG 1343 Mesylate | AG-1343 |
| AG-1346 | AG1343 | AKOS015963185 |
| ARV-SR0121 | AZT/3TC/NLFR combination | C08091 |
| C32H45N3O4S.CH4O3S | C33H49N3O7S2 | CAS-159989-65-8 |
| CCG-100925 | CHEBI:7497 | CHEMBL1205 |
| CPD000469186 | CTK8E9065 | D00899 |
| DSSTox_CID_10777 | DSSTox_GSID_33736 | DSSTox_RID_79093 |
| DTXSID2033736 | HMS2051N05 | HMS2090L17 |
| HMS2233M20 | HMS3261P12 | HMS3715B04 |
| HSDB 7159 | J-009662 | KS-1089 |
| LS-85416 | LY-312857 | MFCD00931436 |
| MLS001055355 | MLS001401378 | MLS006010141 |
| N0986 | NC00175 | NCGC00090782-01 |
| NCGC00090782-03 | NCGC00090782-06 | NCGC00258475-01 |
| NCGC00261320-01 | NFV | NQHXCOAXSHGTIA-SKXNDZRYSA-N |
| NSC-722664 | NSC722664 | Nelfin |
| Nelfinavir (Mesylate) | Nelfinavir Mesylate [USAN] | Nelfinavir Methanesulfonate |
| Nelfinavir mesilate | Nelfinavir mesilate (JAN) | Nelfinavir mesylate |
| Nelfinavir mesylate (USAN/INN) | Nelfinavir mesylate hydrate | Nelfinavir mesylate hydrate, >=98% (HPLC) |
| Nelfinavir methanesulfonate hydrate | Q27107510 | RT-014683 |
| SAM001246655 | SC-79735 | SCHEMBL40942 |
| SMR000469186 | SW197555-2 | SYN3022 |
| Tox21_111021 | Tox21_111021_1 | Tox21_200921 |
| Tox21_500635 | UNII-98D603VP8V | Viracept |
| Viracept (TN) | W-5226 | nelfinavir-mesylate |
| s4282 |